The laser is a very bright,
finely focused light. It passes through the clear cornea, lens and
vitreous without affecting them in any way. Laser surgery shrinks
abnormal new vessels and reduces macular swelling. Treatment is often
recommended for people with macular edema, proliferative diabetic
retinopathy (PDR) and neovascular glaucoma.
Laser surgery is usually
performed in an office setting. For comfort during the procedure, an
anesthetic eyedrop is often all that is necessary, although an anesthetic
injection is sometimes given next to the eye. The patient sits at an
instrument called a slit-lamp microscope. A contact lens is temporarily
placed on the eye in order to focus the laser light on the retina with
pinpoint accuracy.
For macular edema, the laser is
applied near the macula in order to reduce fluid leakage. The main goal
of treatment is to prevent further loss of vision by reducing the
swelling of the macula. It is uncommon for people who have blurred vision
from macular edema to recover normal vision, although some will
experience partial improvement.
A few people may see laser
spots near the center of their vision following treatment. They usually
fade with time, but may not disappear completely.
In PDR, the laser is applied to
all parts of the retina except the macula (called PRP, or panretinal
photocoagulation). This treatment causes abnormal new vessels to shrink
and often prevents them from growing in the future. It also decreases the
chance that vitreous bleeding or retinal distortion will occur.
Panretinal laser has proven to be very effective for preventing severe
vision loss from vitreous hemorrhage and traction retinal detachment.
Side effects of panretinal
laser surgery may include:
- temporary blurred vision for days to a few weeks;
- occasional mild loss of central vision;
- mild to moderate loss of peripheral vision;
- decreased night vision.
Multiple laser treatments over
time may be necessary. Laser surgery does not cure diabetic retinopathy
and does not always prevent further loss of vision. In spite of laser
surgery, some people with PDR develop macular distortion or bleeding into
the vitreous, causing blurred vision. Vitreous hemorrhage may recur and
blood may accumulate faster than the eye can reabsorb it.
Vitrectomy Surgery
Vitrectomy is a surgical
procedure performed in a hospital or ambulatory surgery center operating
room. It is often performed on an outpatient basis or with a short
hospital stay. Either a local or general anesthetic may be used.
During vitrectomy surgery, an
operating microscope and small surgical instruments are used to remove
blood and scar tissue that accompany abnormal vessels in the eye.
Removing the vitreous hemorrhage allows light rays to focus on the retina
again.
Vitrectomy often prevents
further vitreous hemorrhage by removing the abnormal vessels that caused
the bleeding. Removal of the scar tissue helps the retina return to its
normal location. Laser surgery may be performed during vitrectomy
surgery. Vitrectomy surgery may be recommended for:
- thick vitreous blood in young, insulin-dependent diabetic
patients. This is because they are at high risk for traction
detachment, which may be hidden behind the blood.
- thick or repetitive vitreous hemorrhage that does not clear
or significantly interferes with the person’s lifestyle.
- recent traction detachment or distortion of the macula.
To help the retina heal in
place, your ophthalmologist may place a gas bubble in the vitreous space.
The gas bubble will dissolve in one to eight weeks, depending on the type
of gas used. You may be told to keep your head in certain positions while
the gas bubble helps to heal the retina. It is important to follow your
ophthalmologist’s instructions so your eye will heal properly. You will
be advised not to travel by plane or to a high altitude while this bubble
is in your eye, since a rapid increase in altitude can raise your eye
pressure to dangerous levels and could cause vision loss or even
blindness.
Risks of vitrectomy include
infection, bleeding, retinal detachment and high pressure in the eye.
Cataract formation is uncommon right after surgery; however, most
patients often develop a cataract after a number of months or within a
few years.
Advances in treatment
Researchers are studying treatments that target the underlying
biochemical mechanisms that cause diabetic retinopathy. One treatment involves the use of VEGF inhibitors, which hinder the
growth of new blood vessels. Because leakage from these abnormal blood
vessels causes vision loss, preventing their growth could avoid damage to
the retina.
There is now widespread information on this treatment be it for DME or for Proliferative retinopathy. It is a great adjunct to our armamentarium.
On the surgical front we have advanced our techniques and machinery. MicroincisionalVitrectomy Surgery (MIVS) has revolutionized the process making it safer and quicker. The high cut rates of modern vitrectors and its design allows surgeons to get close to the retina enabling perfect dissections. Healing is quicker and patients are more satisfied.
With the advent of Ocriplasmin, there will be further potential in innovation as a separation of the posterior hyaloid is paramount in preventing the severe complication of tractional retinal detachments in patients.
|
1 comment:
Post a Comment